<DOC>
	<DOC>NCT00337545</DOC>
	<brief_summary>Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.</brief_summary>
	<brief_title>Phase II Trial of RAD001 in Refractory Colorectal Cancer</brief_title>
	<detailed_description>Study is completed and closed.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens Measurable disease ECOG 02 CNS disease Chemotherapy or radiotherapy &lt; 4 weeks prior Active bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Refractory</keyword>
</DOC>